Top Banner
MAPLE SYRUP URINE DISEASE BLOCKED PATHWAY OF BCAA CATABOLISM
16
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: MAPLE SYRUP URINE DISEASE BLOCKED PATHWAY OF BCAA CATABOLISM.

MAPLE SYRUP URINE DISEASE

BLOCKED PATHWAY OF BCAA CATABOLISM

Page 2: MAPLE SYRUP URINE DISEASE BLOCKED PATHWAY OF BCAA CATABOLISM.

Its being proposed that therapy with phenyl butyrate in MSUD patients has been associated with a selective reduction in branched-chain amino acids (BCAA) in spite of adequate dietary protein intake.

Hypothesis

Page 3: MAPLE SYRUP URINE DISEASE BLOCKED PATHWAY OF BCAA CATABOLISM.

RATS (Rattus norvegicus)

Age (10-30 days old) The physiology is easier to

monitor in the rat The physiology is more

like the corresponding human condition

The distance effects of drug administration to specific anatomical areas

Over time, a volume of data has developed that will take years to be replicated in the mouse .

RESEARCH SUBJECTS

Page 4: MAPLE SYRUP URINE DISEASE BLOCKED PATHWAY OF BCAA CATABOLISM.

RESEARCH SUBJECTS

Page 5: MAPLE SYRUP URINE DISEASE BLOCKED PATHWAY OF BCAA CATABOLISM.

RESEARCH SUBJECTS

Page 6: MAPLE SYRUP URINE DISEASE BLOCKED PATHWAY OF BCAA CATABOLISM.

BCAA Catabolism

Page 7: MAPLE SYRUP URINE DISEASE BLOCKED PATHWAY OF BCAA CATABOLISM.

E1: 2-oxoisovalerate dehydrogenase, composed itself of two polypeptide chains:

E1-alpha (probably the catalytic subunit) and E1-beta; E1 IS THE MOST COMMON SITE OF

MUTATIONS. E2: dihydrolipoamide acyltransferase. E3: dihydrolipoamide dehydrogenase.

BCKDH

Page 8: MAPLE SYRUP URINE DISEASE BLOCKED PATHWAY OF BCAA CATABOLISM.

Specific Aim: To increase the proportion of active BCKDH.In order to see how phenyl butyrate increases the activity of BCKDH enzyme, the following procedure will be followed;

In vitro testing with fibroblast cells from rat In vivo testing with rats In vivo testing with human subjects

RESEARCH DESIGN

Page 9: MAPLE SYRUP URINE DISEASE BLOCKED PATHWAY OF BCAA CATABOLISM.

In vitro Test (Fibroblast)

Four Rats : 2 healthy control , 2 MSUD patients

2 induced with MSUD via BCAA IV administration

Fibroblast cells are collected from subjects 2mm phenyl

butyrate CIC

Page 10: MAPLE SYRUP URINE DISEASE BLOCKED PATHWAY OF BCAA CATABOLISM.

Based on the success of the in vitro test, a similar test is carried out in humans and the serum levels of BCAA and BCKA data before and after administration of phenyl butyrate generates charts for comparison.

In vivo testing with Human Subjects

Page 11: MAPLE SYRUP URINE DISEASE BLOCKED PATHWAY OF BCAA CATABOLISM.

ResultsIn vivo with Human Subjects

Page 12: MAPLE SYRUP URINE DISEASE BLOCKED PATHWAY OF BCAA CATABOLISM.

PROPOSED MECHANISM

α –keto isovalerate+ CIC + BKD+ Phenyl butyrate +NAD+ + TPP RCOCoA+CO2+NADH+

+ + BKD + + +

+ CO2 +

Page 13: MAPLE SYRUP URINE DISEASE BLOCKED PATHWAY OF BCAA CATABOLISM.

Team A rats are orally given a saline solution for three days

Team B rats are orally given phenyl butyrate for three days .

After 3 days they are sacrificed, livers harvested and analysed using western blot

In vivo with Rats

Results

Page 14: MAPLE SYRUP URINE DISEASE BLOCKED PATHWAY OF BCAA CATABOLISM.

It contains Na+ hence, patients on salt diet cannot use

It can cause drowsiness It contains inactive ingredients that may

cause allergic reactions

Side Effects of Phenyl butyrate

Page 15: MAPLE SYRUP URINE DISEASE BLOCKED PATHWAY OF BCAA CATABOLISM.

INNOVATION: Lactating Porcine Mammary Tissue Catabolizes

Branched-Chain Amino Acids for Glutamine and Aspartate Synthesis

Future Directions